Coverage with Evidence Development: A Road to Accelerated Biomarker Adoption

Oncology biomarkers have the potential to significantly improve the quality and efficiency of health care, but their value hinges on whether payers will support the science. Private payer adoption of CMS' "coverage with evidence development" decisions could provide the appropriate regulatory and reimbursement framework.